logo
Plus   Neg
Share
Email

Quest Diagnostics Acquires Blueprint Genetics; Financial Terms Not Disclosed

Quest Diagnostics (DGX) announced Wednesday that it has acquired Finland-based genetic testing company Blueprint Genetics in an all-cash equity transaction. Financial terms of the transaction were not disclosed.

Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics.

Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development.

Blueprint Genetics brings to Quest a proven platform in specialty genetics, especially gene variant interpretation and reporting, that powerfully differentiates our Advanced Diagnostics offering. The company provides 3,900 targeted single gene and over 200 panel tests spanning 14 medical specialties.

Blueprint Genetics has developed a proven model for delivering highly specialized genetic insights that can scale to serve new patient populations with unmet clinical needs. According to the National Institutes of Health, as many as 7,000 rare diseases exist and as many as 30 million Americans have a rare disease.

Blueprint Genetics has increased its focus and presence in the U.S. through a recently established hub facility in Seattle, Washington. Blueprint Genetics is expected to continue to operate largely independently from its base laboratory in Helsinki, Finland, and a presence in other countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Expedia Group Inc.(EXPE) plans to eliminate about 12 percent of its workforce or 3,000 jobs, following its disappointing 2019 business performance, according to reports citing an internal email from Expedia. The Job cuts will include around 500 at its Seattle headquarters. Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken.
Follow RTT
>